Trial reportHypertension (Dallas, Tex. : 1979)2008
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Trial report in Hypertension (Dallas, Tex. : 1979), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2017Pooled it
- Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.Hypertension (Dallas, Tex. : 1979) · 2019Trial
- Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis.International journal of cardiology · 2013Trial
- Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.Journal of the American Society of Nephrology : JASN · 2013Trial
- Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.Journal of the American Society of Nephrology : JASN · 2011Trial
- Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.Circulation · 2010Trial
- Influence of Atherosclerosis-Associated Risk Factors on Expression of Endothelin Receptors in Advanced Atherosclerosis.International journal of molecular sciences · 2025Article
- Blood Pressure Control in Patients with Diabetic Kidney Disease.Electrolyte & blood pressure : E & BP · 2022Review
- Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Blood pressure control in patients with chronic kidney disease.The Korean journal of internal medicine · 2021Review
- Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?American journal of hypertension · 2019Article
- Novel therapies for diabetic kidney disease.Kidney international supplements · 2018Review
- Article
- Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses.Coronary artery disease · 2014Article
- Random forest fishing: a novel approach to identifying organic group of risk factors in genome-wide association studies.European journal of human genetics : EJHG · 2014Article
- Endothelin, kidney disease, and hypertension.Hypertension (Dallas, Tex. : 1979) · 2013Review
- Endothelin antagonists in hypertension and kidney disease.Pediatric nephrology (Berlin, Germany) · 2013Review
- Resistant hypertension workup and approach to treatment.International journal of hypertension · 2010Article
- New therapeutic approaches to resistant hypertension.Current hypertension reports · 2010Review
- Endothelin, hypertension and chronic kidney disease: new insights.Current opinion in nephrology and hypertension · 2010Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92+/-10 to 80+/-10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93+/-10 and 92+/-11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.